公开(公告)号：US20230296630A1

公开(公告)日：2023-09-21

申请号：US18021021

申请日：2021-08-12

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Peter Kastner ,  Vinzent Rolny ,  Ursula-Henrike Wienhues-Thelen ,  Andre Ziegler ,  David Conen ,  Michael Kuehne ,  Stefan Osswald

IPC: G01N33/68

CPC classification number: G01N33/6896 ,  G01N2800/2871 ,  G01N2800/2814

Abstract: The present invention relates to a method for assessing whether a subject has experienced one or more silent infarcts in a subject, said method comprising a) determining the amounts of the biomarkers Osteopontin, cardiac Troponin, a natriuretic peptide and FABP-3 in a sample from the subject, b) comparing the amounts determined in step a) to references, and c) assessing whether a subject has experienced one or more silent infarcts. The present invention further relates to a method for predicting silent infarcts and/or cognitive decline, and methods for assessing and monitoring of the extent of silent small and large noncortical and cortical infarcts in a subject. Further encompassed by the present invention are the corresponding uses.

公开(公告)号：US20230341419A1

公开(公告)日：2023-10-26

申请号：US18021047

申请日：2021-08-12

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Vinzent Rolny ,  Ursula-Henrike Wienhues-Thelen ,  Andre Ziegler ,  David Conen ,  Stefan Osswald ,  Michael Kuehne ,  Peter Kastner

IPC: G01N33/68

CPC classification number: G01N33/6896 ,  G01N2800/2871 ,  G01N2800/52 ,  G01N2800/50

Abstract: The present invention relates to a method for assessing whether a subject has experienced one or more silent infarcts in a subject, said method comprising a) determining the amount of the biomarker ESM-1 in a sample from the subject, b) comparing the amount determined in step a) to a reference, and c) assessing whether a subject has experienced one or more silent infarcts. The present invention further relates to a method for predicting silent infarcts and/or cognitive decline, and methods for assessing and monitoring of the extent of silent small and large noncortical and cortical infarcts in a subject. Further encompassed by the present invention are the corresponding uses.

公开(公告)号：US11946938B2

公开(公告)日：2024-04-02

申请号：US16899629

申请日：2020-06-12

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Ursula-Henrike Wienhues-Thelen ,  Johann Karl ,  Peter Kastner ,  Vinzent Rolny ,  Andre Ziegler ,  David Conen

IPC: G01N33/53 ,  G01N33/68

CPC classification number: G01N33/6893 ,  G01N2333/4745 ,  G01N2333/515 ,  G01N2800/326 ,  G01N2800/50

Abstract: The present disclosure demonstrates a method for predicting the risk of stroke of a subject and a method for improving the prediction accuracy of a clinical stroke risk score. The methods are based on the determination of the amount of Angiopoietin-2 (Ang-2) and/or the amount of Insulin-like growth factor-binding protein 7 (IGFBP7) in a sample from a subject. Moreover, disclose is the use of i) the biomarker Ang-2 and/or the biomarker IGFBP7, and/or ii) at least one detection agent that specifically binds to Ang-2 and/or at least one detection agent that specifically binds to IGFBP7 in a sample from a subject for predicting the risk of stroke of said subject.

公开(公告)号：US20230314452A1

公开(公告)日：2023-10-05

申请号：US18021085

申请日：2021-08-12

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Peter Kastner ,  Vinzent Rolny ,  Ursula-Henrike Wienhues-Thelen ,  Andre Ziegler ,  David Conen ,  Stefan Osswald ,  Michael Kuehne

IPC: G01N33/68

CPC classification number: G01N33/6896 ,  G16H50/30

Abstract: The present invention relates to a method for assessing whether a subject has experienced one or more silent infarcts in a subject, said method comprising a) determining the amount of IGFBP7 in a sample from the subject, b) comparing the amount determined in step a) to a reference, and c) assessing whether a subject has experienced one or more silent infarcts. The present invention further relates to a method for predicting silent infarcts and/or cognitive decline, and methods for assessing and monitoring of the extent of silent small and large noncortical and cortical infarcts in a subject. Further encompassed by the present invention are the corresponding uses.

公开(公告)号：US20200300869A1

公开(公告)日：2020-09-24

申请号：US16899629

申请日：2020-06-12

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Ursula-Henrike Wienhues-Thelen ,  Johann Karl ,  Peter Kastner ,  Vinzent Rolny ,  Andre Ziegler ,  David Conen

IPC: G01N33/68

Abstract: The present disclosure demonstrates a method for predicting the risk of stroke of a subject and a method for improving the prediction accuracy of a clinical stroke risk score. The methods are based on the determination of the amount of Angiopoietin-2 (Ang-2) and/or the amount of Insulin-like growth factor-binding protein 7 (IGFBP7) in a sample from a subject. Moreover, disclose is the use of i) the biomarker Ang-2 and/or the biomarker IGFBP7, and/or ii) at least one detection agent that specifically binds to Ang-2 and/or at least one detection agent that specifically binds to IGFBP7 in a sample from a subject for predicting the risk of stroke of said subject.